Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by Truist Financial to “Strong-Buy” Rating

Truist Financial upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

A number of other research firms also recently weighed in on CPRX. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Finally, Zacks Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Three investment analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Strong Buy” and an average price target of $34.00.

Catalyst Pharmaceuticals Trading Up 3.2%

CPRX opened at $23.80 on Wednesday. The company has a market cap of $2.91 billion, a price-to-earnings ratio of 14.08, a price-to-earnings-growth ratio of 0.67 and a beta of 0.75. The stock has a fifty day simple moving average of $23.97 and a two-hundred day simple moving average of $22.64. Catalyst Pharmaceuticals has a 12-month low of $19.05 and a 12-month high of $26.58.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust increased its holdings in shares of Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 469 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in Catalyst Pharmaceuticals by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 472 shares in the last quarter. Jones Financial Companies Lllp grew its position in Catalyst Pharmaceuticals by 14.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 498 shares during the last quarter. Lifestyle Asset Management Inc. grew its position in Catalyst Pharmaceuticals by 3.4% during the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after purchasing an additional 553 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).